



## Robert J. Paradiso

Partner  
Chair, Chemicals & Life Sciences Patent Practice

New Jersey  
T: +1 973.597.2404 | F: +1 973.597.2405  
rparadiso@lowenstein.com

Robert's practice is focused on the life sciences and chemical industries. Over the course of his career, he has counseled clients on the discovery, design, and protection of many successful therapeutic and diagnostic products with important commercial and humanitarian benefits. He is recognized by *Chambers USA* (2012-2017) as a "phenomenal" lawyer and "practical, strategic thinker" who "is very good at thinking outside the box and looking at every angle and advising on how to best move forward."

As a registered pharmacist, Robert is able to speak the same language as the researchers, managers, and investors with whom he interacts daily. He is particularly adept at analyzing complex issues and effectively crafting, communicating, and implementing solutions that achieve his clients' goals—whether for raising capital, closing the deal, or obtaining a bet-the-company patent.

Clients benefit from Robert's significant experience in virtually all aspects of intellectual property law, including:

- Patent prosecution
- Noninfringement
- Patentability
- Litigation
- Freedom to operate
- Technology transfer

He also regularly advises clients on product acquisition and divestiture, joint ventures and alliances, technology licensing, outsourcing, and other technology-related transactions.

Robert serves as an adjunct professor at Seton Hall University School of Law School, where he teaches patent drafting and prosecution.

## EXPERIENCE

---

- > Obtained a groundbreaking patent that is listed in the FDA Orange Book for a tamper-resistant formulation of an FDA-approved narcotic analgesic.
- > Obtained Orange Book-listed patents for a specialty pharmaceutical company specializing in acute hospital care. The patents encompass four currently marketed formulations of an injectable antihypertensive product and were the driving force for the eventual acquisition of the company.
- > Obtained multiple patents covering a Phase III injectable product for the treatment of adverse effects of chemotherapy.
- > Represented a leading U.S. medical school in prosecuting and procuring patents directed to specialized tests that are capable of detecting latent tuberculosis in patients.
- > Performed an IP analysis for a leading financial services firm in connection with an investment in a biopharmaceutical company developing a genetically personalized therapeutic agent.

## HONORS & AWARDS

---

- > **Chambers USA: America's Leading Lawyers for Business (2012-2021)**  
Recognized in the Intellectual Property category.  
Clients note Robert Paradiso "is very good at thinking outside the box, and looking at every angle and advising on how best to move forward." Sources praise Robert for having the ability to "spin gold out of hay" and being "very smart, easy to deal with and a practical strategic thinker."
- > **Intellectual Asset Management (IAM) Patent 1000 (2018-2020)**  
Listed among the preeminent patent prosecution practitioners in IAM's Patent 1000 - The World's Leading Patent Practitioners

## NEWS & INSIGHTS

---

## In the Media

> August 3, 2020

Lowenstein's representation of **Spring Bank Pharmaceuticals, Inc.** (Nasdaq: SBPH) in entering into a definitive share exchange agreement with F-star Therapeutics Limited to acquire all of the outstanding share capital of F-star in exchange for newly issued shares of Spring Bank in an all-stock transaction is highlighted in the **Global Legal Chronicle**. The Lowenstein deal team included **John D. "Jack" Hogoboom, Daniel C. Porco**, and Madeline Roe (Corporate); **Brian A. Silikovitz** and **Kristin V. Taylor** (Tax); **Robert J. Paradiso** (Patent Counseling & Prosecution); and **Andrew E. Graw** and **Christine Osvald-Mruz** (Executive Benefits & Executive Compensation). **View Lowenstein's news announcement about this transaction.**

> July 29, 2020

Lowenstein's representation of **Spring Bank Pharmaceuticals, Inc.** in its definitive share exchange agreement with F-star to combine as F-star Therapeutics, Inc. is reported in **Canada Stock Watch**. The Lowenstein deal team included **John D. "Jack" Hogoboom, Daniel C. Porco**, and **Madeline Roe** (Corporate); **Brian A. Silikovitz** and **Kristin V. Taylor** (Tax); **Robert J. Paradiso** (Patent Counseling & Prosecution); and **Andrew E. Graw** and **Christine Osvald-Mruz** (Executive Benefits & Executive Compensation). **View Lowenstein's news announcement about this transaction.**

> June 22-26, 2020

**Citybizlist, Marketwatch, GlobeNewswire, M&A Navigator, MassDevice.com**, the **Global Legal Chronicle, Law360**, and **MD and DI Online** report the sale of Lowenstein client **Artegraft** to LeMaitre Vascular for \$90 million. The Lowenstein deal team includes **Michael J. Lerner, Michael Reinhardt, Annie Nazarian Davydov, Darren Goodman, Robert J. Paradiso, Mary E. Storella, Brian A. Silikovitz, Sophia Mokotoff, James C. Shehan, Norman W. Spindel, Taryn E. Cannataro, Danielle M. Falzone**, and **Jesse S. O'Connell**. (subscription required to access certain content) **View Lowenstein's news announcement about this transaction.**

> June 22, 2020

Lowenstein's representation of issuer **Celldex Therapeutics, Inc.** (Celldex) (Nasdaq: CLDX) in connection with the company's approximately \$150 million public offering of common stock is highlighted in the **Global Legal Chronicle**. The Lowenstein team included **Anthony O. Pergola, Alan Wovsaniker, Kate Basmagian, Alexander Dinur**, Madeline Roe, **Sarah Gore**, and **Robert J. Paradiso**. **View Lowenstein's news announcement about this transaction.**

> May 7, 2020

Lowenstein's representation of **Delcath Systems, Inc.** in an underwritten public offering of shares and warrants is noted in the **Global Legal Chronicle**. The Lowenstein deal team included **John D. "Jack" Hogoboom, Robert J. Paradiso, Brian A. Silikovitz, James C. Shehan, Sarah P. Cole**, Michael T. Melchiorre, Erica Perlmutter, and **Kristin V. Taylor**. **View Lowenstein's news announcement about this transaction.**

## SPEAKING ENGAGEMENTS

---

> Presenter, **National Society of Inventors**, December 11, 2018

## EDUCATION

---

> St. John's University School of Law (J.D. 1994)

> Long Island University (B.S. 1990), Pharmacy

## ADMISSIONS

---

> New York

> New Jersey

> United States Patent and Trademark Office